Finance > Venture Deals Database > Venture Transactions Database > Monthly Deals (All) > April 2006 VC Transactions
Theranox

Tech Company Financing Transactions

Theranox Funding Round

Theranox closed a $14 million Series A funding round on 4/10/2006. Investors included NewSpring Capital and Quaker Partners.

Transaction Overview

Company Name

Theranox

Announced On

4/10/2006

Transaction Type

Venture Equity

Amount

$14,000,000

Round

Series A

Investors

NewSpring Capital (Lead Investor) (Zev Scherl)

Quaker Partners (Lead Investor) (Matthew Rieke)

Proceeds Purpose

Theranox plans to use the financing to fund clinical trials and commercialize the use of gaseous Nitric Oxide for the treatment of chronic wounds such as Diabetic Ulcers and Venous Stasis Ulcers, as well as for other topical applications such as the treatment of post-surgical infections.

Company Information

Company Status

Out of Business

Industry

Biopharmaceutical

Mailing Address

10 Progress Place
Voorthees, NJ 08043
USA

Phone

856-424-3845

Website

Email Address

Not Recorded

Overview

Theranox, Inc. is a venture-backed biopharmaceutical company dedicated to exploring medical applications of topically applied gaseous Nitric Oxide (gNO).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

President

Frank McCaney

Browse more venture capital transactions:

Prev: 4/6/2006: Radar Networks venture capital transaction
Next: 4/10/2006: Aperto Networks venture capital transaction

Share this article

About Database of VC Transactions

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary